Trial Design and Participants
This was a prospective, multicenter, single-group, phase 2 clinical trial. Patients were enrolled from March 6, 2017, through November 9, 2021. All participating centers received approval from their institutional review boards. All patients provided written informed consent. This study followed the Transparent Reporting of Evaluations With Nonrandomized Designs (The trial design and patient selection criteria were detailed previously.